Liu Y - Search Results

1

Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.

Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J. Liu Y, et al. J Gene Med. 2004 Aug;6(8):857-68. doi: 10.1002/jgm.576. J Gene Med. 2004. PMID: 15293344

2

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.

Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J. Liu Y, et al. Cancer Gene Ther. 2002 Feb;9(2):202-8. doi: 10.1038/sj.cgt.7700429. Cancer Gene Ther. 2002. PMID: 11857039

3

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors.

Liu Y, Huang H, Saxena A, Xiang J. Liu Y, et al. Cancer Gene Ther. 2002 Jun;9(6):533-42. doi: 10.1038/sj.cgt.7700466. Cancer Gene Ther. 2002. PMID: 12032664

4

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity.

Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Liu Y, et al. Leuk Res. 2002 Aug;26(8):757-63. doi: 10.1016/s0145-2126(02)00002-4. Leuk Res. 2002. PMID: 12191571

5

Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.

Huang H, Liu Y, Xiang J. Huang H, et al. Among authors: liu y. Cell Immunol. 2002 May-Jun;217(1-2):12-22. doi: 10.1016/s0008-8749(02)00508-7. Cell Immunol. 2002. PMID: 12425997

6

Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.

Liu Y, Huang H, Chen Z, Zong L, Xiang J. Liu Y, et al. J Gene Med. 2003 Aug;5(8):668-80. doi: 10.1002/jgm.387. J Gene Med. 2003. PMID: 12898636

7

Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.

Liu Y, Xia D, Li F, Zheng C, Xiang J. Liu Y, et al. Cancer Gene Ther. 2005 Feb;12(2):122-32. doi: 10.1038/sj.cgt.7700757. Cancer Gene Ther. 2005. PMID: 15565183

8

Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.

Liu Y, Bi X, Xu S, Xiang J. Liu Y, et al. Cancer Res. 2005 Jun 1;65(11):4955-62. doi: 10.1158/0008-5472.CAN-04-3957. Cancer Res. 2005. PMID: 15930318

9

Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.

Liu Y, Qureshi M, Xiang J. Liu Y, et al. Cancer Biother Radiopharm. 2002 Feb;17(1):11-8. doi: 10.1089/10849780252824028. Cancer Biother Radiopharm. 2002. PMID: 11915168

10

A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells.

Xiang J, Huang H, Liu Y. Xiang J, et al. Among authors: liu y. J Immunol. 2005 Jun 15;174(12):7497-505. doi: 10.4049/jimmunol.174.12.7497. J Immunol. 2005. PMID: 15944248

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208,467 results

Search Page

Filters